Embattled College of Charleston men's basketball coach Doug Wojcik is on the road recruiting a week after school officials said he would not be making any recruiting trips.

Wojcik was in Augusta on Thursday and spent Friday in Atlanta. College of Charleston released a statement July 8 that said Wojcik would not be on the road recruiting with his assistant coaches.

Asked what has changed and would Wojcik return as coach, Mike Robertson, the school's director of media relations, said Friday: "I've talked to our people and we can't say anything about men's basketball."

Director of athletics Joe Hull referred questions to Michael Haskins, the school's executive vice president for marketing and communications, who did not return calls. Wojcik also could not be reached for comment.

Wojcik's future at the College of Charleston has been in question after a 50-page report surfaced, alleging that the coach was verbally abusive.

Wojcik has three years remaining on his contract which pays $400,000 annually. He agreed to be suspended without pay for the month of August.

Wojcik's attorney, Scott Tompsett of Kansas City, said Wednesday he had "no comment on it other than what we've released."

Shortly after the investigation became public, Tompsett issued a statement saying Wojcik intended to fulfill the remaining three years of his contract.

"I'm sincerely remorseful and apologize to those I've hurt," Wojcik said in the statement. "I've already started making amends and working on correcting my actions. The College and I are grateful these concerns were brought to our attention, and every effort will be made to improve relations between myself and all members of the men's basketball program."

Wojcik, who was fired by Tulsa in 2012 after compiling a 140-92 record, was hired at Charleston in April of that year to replace Bobby Cremins. The Cougars were 24-11 in his first season and advanced to the final of the Southern Conference tournament. The Cougars jumped to the more competitive CAA this past season and were 14-18 overall.